Celecoxib plus topical flurbiprofen patch versus celecoxib alone for symptomatic knee OA: a randomized controlled trial

塞来昔布 医学 骨关节炎 随机对照试验 可视模拟标度 氟比洛芬 麻醉 沃马克 临床试验 生活质量(医疗保健) 口服 不利影响 内科学 布洛芬 外科 疼痛评分 患者满意度 止痛药
作者
Kaibo Sun,Min Pu,Huaixian Zhang,Liangtao Bai,Xiaoxiao Wu,Ling Fan,Qinsheng Hu
出处
期刊:Rheumatology [Oxford University Press]
卷期号:65 (9): keag488-
标识
DOI:10.1093/rheumatology/keag488
摘要

OBJECTIVES: Rapid symptom control may facilitate earlier mobility and self-management in symptomatic knee OA (KOA), but evidence for combining oral and topical NSAIDs remains limited. This study aimed to determine whether adding a topical flurbiprofen patch to oral celecoxib provides greater short-term improvements in pain, physical function, quality of life and patient global assessment (PGA) than oral celecoxib alone in patients with symptomatic KOA. METHODS: In this open-label randomized controlled trial conducted at a tertiary academic hospital from January 2024 to March 2025, 90 patients with chronic inflammatory symptomatic KOA were randomized 1:1 to receive either oral celecoxib 200 mg once daily or celecoxib plus topical flurbiprofen patch twice daily. Outcomes were assessed at baseline and on days 3, 7 and 14. Primary outcomes were pain severity by visual analogue scale (VAS) and functional impairment by WOMAC. Secondary outcomes included quality of life by SF-36 and PGA. RESULTS: Eighty-nine patients completed the study (45 celecoxib; 44 combination therapy). Baseline characteristics were comparable between the groups. Compared with celecoxib alone, combination therapy produced greater early pain relief, with larger VAS reductions on day 3 (3.4 ± 0.9 vs 2.0 ± 0.8, P < 0.01) and day 7 (3.9 ± 1.0 vs 3.3 ± 1.0, P = 0.02), but not day 14. WOMAC improvement was greater in the combination group on days 3, 7 and 14 (all P < 0.01). At day 14, SF-36 health domain scores and PGA ratings were also higher with combination therapy. CONCLUSIONS: Adding topical flurbiprofen patch to oral celecoxib provided faster early improvement in pain and function and better short-term patient-reported outcomes in symptomatic KOA. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR1800014584.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被芳华如梦采纳,获得10
刚刚
leizhengyu发布了新的文献求助10
刚刚
初景发布了新的文献求助10
刚刚
朝夕发布了新的文献求助10
1秒前
1秒前
赘婿的应助被彼岸花采纳,获得10
1秒前
雨莫完成签到,获得积分10
2秒前
念汐发布了新的文献求助10
2秒前
2秒前
2秒前
小蘑菇的应助被Grace采纳,获得10
3秒前
Goldensun发布了新的文献求助10
3秒前
4秒前
4秒前
4秒前
未见阑珊完成签到,获得积分10
4秒前
Ava的应助被cuipi采纳,获得30
6秒前
淡然梦芝发布了新的文献求助20
7秒前
7秒前
搜集达人的应助被求助文献采纳,获得10
8秒前
YY发布了新的文献求助10
8秒前
Pp发布了新的文献求助10
8秒前
yanghy完成签到,获得积分10
9秒前
10秒前
Goldensun完成签到,获得积分10
10秒前
Atlantis30发布了新的文献求助10
11秒前
jsm5566完成签到,获得积分10
11秒前
FashionBoy的应助被开朗不凡采纳,获得10
11秒前
pp发布了新的文献求助10
11秒前
ww完成签到 ,获得积分10
12秒前
jjjwwww完成签到,获得积分10
12秒前
闪闪完成签到,获得积分10
12秒前
13秒前
Peng发布了新的文献求助20
13秒前
Charlie完成签到,获得积分10
13秒前
14秒前
15秒前
baijie发布了新的文献求助10
15秒前
君澔发布了新的文献求助10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188785
求助须知:如何正确求助?哪些是违规求助? 9576421
关于积分的说明 21847553
捐赠科研通 7786814
什么是DOI,文献DOI怎么找? 3435417
关于科研通互助平台的介绍 2559647
邀请新用户注册赠送积分活动 2482366